Herbal extracts curcumin and Qing Dai induce remission in active ulcerative colitis patients

Written By : Aditi |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-06-23T20:00:54+05:30 | Updated On 23 Jun 2023 8:01 PM IST

A study published in Clinical Gastroenterology and Hepatology, American Gastroenterological Association by Shomron Ben-Horin et al. and the team have concluded that in active UC patients, a herbal combination of curcumin-QingDai (CurQD) induces remission.

Researchers from the Department of Gastroenterology, Sheba Medical Center, Israel Sackler School of Medicine said that We evaluated the efficacy of the herbal combination of curcumin-QingDai (CurQD) in active ulcerative colitis (UC).

Forty-two adults with a history of active UC were randomly assigned to an enteric-coated pill containing 3 g of curcumin and Qing Dai (CurQD) or a placebo for eight weeks.

The study results are:

In part 1, 7/10 patients responded, and 3/10 achieved clinical remission.
Of 42 patients in part 2, week eight coprimary outcome was achieved in 43% and 8% of CurQD and placebo patients, respectively.
Of the CurQD patients, 43% met the coprimary endpoint compared to 8% of the placebo.
Clinical response was observed in 86% of the CurQD patients vs 31% of the placebo patients.
Clinical remission was observed in 50% of CurQD and 8% of placebo patients.
Endoscopic improvement was observed in 75% of the CurQD patients vs 20% of the placebo patients.
The responses were maintained at 16 weeks with maintenance curcumin alone.
There were comparable adverse events between groups.
By week 16, curcumin-maintained clinical response, clinical remission and clinical-biomarker response rates were 93%, 80% and 40%, respectively.
CurQD upregulated mucosal CYP1A1 expression. This was not observed in the placebo.

They said, “In active ulcerative colitis patients, CurQD is effective for inducing response and remission. The AhR-pathway may merit further study as a potential UC treatment target.”

The study's main limitations were the modest cohort size and the absence of histologic outcomes.

BDS, MDS in Periodontics and Implantology

Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751